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Abstract
The recent 2009 pandemic H1N1 virus infection in humans has resulted in nearly 5,000 deaths worldwide. Early
epidemiological findings indicated a low level of infection in the older population (.65 years) with the pandemic virus, and
a greater susceptibility in people younger than 35 years of age, a phenomenon correlated with the presence of cross-
reactive immunity in the older population. It is unclear what virus(es) might be responsible for this apparent cross-
protection against the 2009 pandemic H1N1 virus. We describe a mouse lethal challenge model for the 2009 pandemic
H1N1 strain, used together with a panel of inactivated H1N1 virus vaccines and hemagglutinin (HA) monoclonal antibodies
to dissect the possible humoral antigenic determinants of pre-existing immunity against this virus in the human population.
By hemagglutinination inhibition (HI) assays and vaccination/challenge studies, we demonstrate that the 2009 pandemic
H1N1 virus is antigenically similar to human H1N1 viruses that circulated from 1918–1943 and to classical swine H1N1
viruses. Antibodies elicited against 1918-like or classical swine H1N1 vaccines completely protect C57B/6 mice from lethal
challenge with the influenza A/Netherlands/602/2009 virus isolate. In contrast, contemporary H1N1 vaccines afforded only
partial protection. Passive immunization with cross-reactive monoclonal antibodies (mAbs) raised against either 1918 or A/
California/04/2009 HA proteins offered full protection from death. Analysis of mAb antibody escape mutants, generated by
selection of 2009 H1N1 virus with these mAbs, indicate that antigenic site Sa is one of the conserved cross-protective
epitopes. Our findings in mice agree with serological data showing high prevalence of 2009 H1N1 cross-reactive antibodies
only in the older population, indicating that prior infection with 1918-like viruses or vaccination against the 1976 swine
H1N1 virus in the USA are likely to provide protection against the 2009 pandemic H1N1 virus. This data provides a
mechanistic basis for the protection seen in the older population, and emphasizes a rationale for including vaccination of
the younger, naı ¨ve population. Our results also support the notion that pigs can act as an animal reservoir where influenza
virus HAs become antigenically frozen for long periods of time, facilitating the generation of human pandemic viruses.
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Introduction
Influenza A viruses (IAV), members of the Orthomyxoviridae
family, cause severe respiratory diseases in humans with an
average mortality rate of 36,000/year in the United States alone
[1]. Apart from yearly seasonal outbreaks, IAV can cause frequent
epidemics and occasional pandemics in humans [2,3]. Vaccination
has been one of the most effective means of protection against
IAV. Vaccine induced production of antibodies against the viral
surface glycoprotein hemagglutinin (HA) is crucial for immune
protection [4]. The HA plays a critical role in the virus life cycle by
mediating virus binding to sialic acid containing receptors on the
cell surface and fusion of viral and endosomal membranes, leading
to viral entry into the host cell [2,5]. HA-specific antibodies have
been demonstrated to block the IAV infection by preventing
receptor binding and/or fusion. However, the HA protein, due to
antibody mediated immune selection pressure, undergoes rapid
antigenic evolution by accumulation of mutations (‘‘antigenic
drift’’) and through genetic reassortments of segments (‘‘antigenic
shift’’). In the 20
th century, influenza virus caused three pandemics
in humans: 1918 ‘‘Spanish influenza’’ (H1N1), 1957 ‘‘Asian
influenza’’ (H2N2) and 1968 ‘‘Hong Kong influenza’’ (H3N2)
[6,7]. In April 2009 the Centers for Disease Control and
Prevention (CDC) of the United States of America announced
the detection of a novel strain of influenza virus in humans.
Further investigation revealed that this novel virus derived its
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sustained human-to-human transmission of this novel virus
throughout the world on June 11th, the World Health Organi-
zation (WHO) raised the worldwide pandemic alert level to phase
6 (e.g. ongoing global spread and community level outbreaks in
multiple parts of world). All of the past pandemics and the recent
2009 swine-origin IAV H1N1 pandemic have been caused by IAV
strains carrying an antigenically novel HA segment in populations
immunologically naı ¨ve to that particular HA.
Apart from humans, IAV can infect a variety of species
including poultry, aquatic birds, horses, pigs, dogs and seals [8,9].
Aquatic wild birds are considered to be natural reservoirs of
different subtypes of IAV, and pigs, in addition to harbor swine
influenza virus strains, are thought to serve as ‘‘mixing vessels’’ for
genetic reassortments of viral segments between avian and human
influenza virus strains [8,10]. Sometime during the 1918–20
pandemic, IAV H1N1 resembling the 1918 pandemic virus was
introduced into the domestic swine population [11,12]. Until
today, these H1N1 viruses, referred as classical swine H1N1, have
circulated in the swine population with relatively modest changes
in HA antigenicity [13]. In contrast to HA antigenic stasis in
swine, descendants of the 1918 virus circulated in humans with
considerable antigenic drift in HA, until they were replaced by the
1957 H2N2 pandemic virus [4]. In 1978, an H1N1 virus
resembling a late 1950’s human H1N1 virus reemerged in the
human population [14,15]. From 1977 to the present day, both
H3N2 and H1N1 viruses co-circulate in humans. In addition, in
1976, a swine H1N1 IAV (classical H1N1) outbreak was reported
among soldiers at the Fort Dix Army base in New Jersey [16,17].
Because no H1N1 viruses had circulated in humans since 1957,
the Fort Dix outbreak raised fears of an H1N1 pandemic.
Therefore, a vaccine based upon an inactivated A/NJ/76 (H1N1)
virus was developed and administered to nearly 40 million people
in the United States. However, the 1976 swine H1N1 virus did not
cause a pandemic and no infections were reported outside of Fort
Dix.
Although several infections with swine IAV have been reported
in humans, such infections have been rare [18,19,20,21].
Surprisingly, the current 2009 pandemic H1N1 has proved to
be very efficient in human-to-human transmission compared to
previous swine influenza viruses. Apart from lack of pre-existing
immunity against this virus in most humans, it is still unclear
what viral genetic factors contribute to this higher transmission
rate. It is interesting to note that recent epidemiological data
indicate a higher rate of confirmed 2009 H1N1 infection in
individuals younger than 18 years of age as compared to
older individuals [22]. It is speculated that some of the older
population may have been exposed to a virus antigenically
similar to 2009 H1N1. Nevertheless, it is currently unknown
which specific virus or viruses that circulated in the past and
during what years, might be responsible for this apparent serum
cross-reactivity reported in the older population (above 65 years
of age) [23,24,25].
In this study, using a lethal mouse model system of the current
2009 H1N1 virus, we tested the efficacy of a panel of 11 different
virus vaccines spanning from 1918 to 2009. We demonstrate that
mice immunized with inactivated vaccines based on human H1N1
virus from 1918 to 1943 or based on classical swine H1N1 viruses
confer complete protection from death against a lethal challenge
with the 2009 H1N1 virus. In contrast, vaccination of mice with
inactivated human H1N1 viruses isolated after 1950, including
contemporary H1N1 viruses, offered only partial protection and
resulted in greater morbidity due to 2009 H1N1 virus infection. In
agreement with vaccination/challenge studies, pre-challenge sera
from mice vaccinated with 1918, and classical swine antigens show
neutralization of hemagglutination of 2009 H1N1 virus. In
addition, we isolated anti-HA specific monoclonal antibodies
(mAb) that have cross-reactivity against 1918 and 2009 H1N1
HA’s. In challenge experiments, these mAbs offer complete
protection against death by the 2009 H1N1 virus following
passive immunization. Analysis of escape mutant viruses selected
in the presence of these mAbs mapped to antigenic site Sa.
Together, these data suggest that the novel 2009 pandemic H1N1
virus shares a great level of antigenic similarity to the 1918 virus
and that site Sa is highly conserved in these two viruses. These
results agree well with epidemiological data which indicate that the
older population (age .65) are less susceptible to the 2009 H1N1
[24,25,26] and with data arising from two recent studies that
demonstrated high prevalence of cross-neutralizing antibodies in
people born before 1940 [27,28]. Taken together, our observa-
tions provide a rationale for the protection observed in the older
population to the 2009 H1N1 pandemic virus and the greater
susceptibility seen in younger individuals. Thus, our data indicate
that individuals that have been previously exposed to and contain
antibodies against 1918-like H1N1 viruses or classical swine H1N1
are likely to be protected against the novel swine-origin 2009
H1N1 virus.
Materials and Methods
Ethics statement
All animal procedures performed in this study are in accordance
with Institutional Animal Care and Use Committee (IACUC)
guidelines, and have been approved by the IACUC of Mount
Sinai School of Medicine.
Author Summary
Influenza A viruses generally infect individuals of all ages
and cause severe respiratory disease in very young
children and elderly people (.65 years). However, the
2009 pandemic H1N1 virus infection is predominantly seen
in children and adults (,35 years of age), but rarely in
people older than 65 years of age. Recent serological
studies indicate that older people carry antibodies that
recognize the 2009 H1N1 virus. This suggests that they
may have been exposed to or vaccinated with an influenza
virus similar to 2009 H1N1 virus. In this study, we wanted
to identify the older H1N1 virus(es) that may confer
protection to the elderly population. Using 11 different
inactivated influenza A viruses that have circulated
between 1918 to 2007, we immunized mice and chal-
lenged them with a lethal dose of the 2009 novel H1N1
virus. We find that mice vaccinated with human H1N1
viruses that circulated in 1918 and in 1943 were protected
from the 2009 H1N1 virus. Also, the 1976 swine origin
H1N1 virus, against which nearly 40 million people were
immunized in 1976 in the United States, protects mice
from death by the 2009 H1N1 virus. This indicates that
people carrying antibodies against H1N1 viruses that
circulated between 1918–1943 and to the 1976 swine
origin H1N1 virus are likely to be protected against the
2009 pandemic H1N1. Importantly, our data underscores
the significance of vaccinating people under 35 year of
age, since the majority of them do not have protective
antibodies against the 2009 H1N1, and provide a possible
mechanism by which pandemic viruses could arise from
antigenically frozen influenza viruses harbored in the
swine population.
1918-Like Viruses Protect against 2009 SOIV H1N1
PLoS Pathogens | www.plospathogens.org 2 January 2010 | Volume 6 | Issue 1 | e1000745Cell lines
Human embryonic kidney (293T) cells were maintained in
DMEM supplemented with 10% FBS and 1000u/ml penicillin/
streptomycin. Madin–Darby canine kidney (MDCK) cells were
maintained in MEM supplemented with 10% FBS and penicillin/
streptomycin. Reagents for cell culture were purchased from
Gibco Life Technologies.
Virus strains
H1N1 viruses used in this study are as follows: A/Swine/Iowa/
30 (Sw/30), A/Puerto Rico/8/34 -MSSM (PR8), A/Weiss/43
(Wei/43), A/New Jersey/8/1976 (NJ/76), A/USSR/92/77
(USSR/77), A/Houston/20593/84 (Hou/84), A/Texas/36/
1991 (Tx/91), A/Brisbane/59/2007 (Bris/59/07), A/California/
04/2009 (Cal/09) and A/Netherlands/602/2009 (Neth/09). A/
Northern Territory/60/1968 (NT/68) and A/Brisbane/10/2007
(Bris/10/07) were used as H3N2 controls. All experiments
involving 2009 H1N1 viruses were conducted under Biosafety
level 3 (BSL3) conditions for animal work and Biosafety level 2
with BSL3 practices laboratory conditions for in vitro work, in
accordance with guidelines of the Centers for Disease Control and
Prevention. Cal/09 and Neth/09 virus stocks used for mice
experiments were all grown in MDCK cells. All other viruses were
grown in 10d old eggs at 37uC for 2–3 days.
Rescue of Cal/09 vaccine strain
The recombinant influenza A virus carrying HA/NA from Cal/
09 and the internal six genes from PR8, referred to as Cal/09 6:2
in the reminder of the study, was generated as described previously
[29]. Briefly, 293T cells were transfected with eight ambisene pDZ
vectors encoding the 8 viral genes and proteins and 24 h post-
transfection, the supernatant was inoculated into 8-day-old
embryonated chicken eggs. The allantoic fluid was harvested after
3 days of incubation at 35uC. The rescued virus was plaque
purified in MDCK cells and re-grown in 10-day-old embryonated
chicken eggs.
Vaccine preparation
All viruses used to prepare inactivated vaccines were grown in
10d old eggs at 37uC for 2 days. After the clarification of debris in
the allantoic fluid by low speed centrifugation, the viruses were
pelleted on a 30% sucrose cushion by centrifugation at
25,000 rpm for 2hr. The viral pellet was resuspended in calcium
borate buffer pH=7.0 (143mM Sodium chloride, 10mM Calcium
chloride, 20mM Boric acid 2.5mM sodium borate) at 1mg/ml
concentration calculated by the Bradford method (Bio-Rad
laboratories, Hercules, CA) and the virus was inactivated by
formaldehyde (0.9% final conc.). For the Cal/09 vaccination
group, in place of wild type virus, a Cal/09 6:2 was used (described
above). For the 1918 virus-based vaccine, virus-like particles (VLP)
were used for vaccination. VLPs were produced by co-transfecting
HA (A/South Carolina/1/18) and NA (A/Brevig Mission/1/18)
into 293T cells as previously described [30]. Released VLPs were
purified on a 30% sucrose cushion. Vaccine doses used were based
on the amount of total protein concentration measured by the
Bradford method.
Generation of HA-specific mouse monoclonal antibodies
Pandemic H1N1 2009 and 1918 HA-specific mouse mAbs were
generated by the hybridoma shared research facility at Mount
Sinai School of Medicine, New York, NY. For the generation of
2009 H1N1 HA-specific antibodies, 6-week-old BALB/C mice
were infected intranasally with 5610
4 pfu of influenza virus Cal/
09. Four weeks later, the mice were given 2610
7 pfu of Cal/09 6:2
intravenously to boost Cal/09 HA-specific B cells. Three days
after the boost the spleen was harvested and B cells from the
spleen were fused with SP2/0 myeloma cells by the addition of
polyethylene glycol. The supernatants of the resulting hybridomas
were tested by immunofluorescence staining on 293T cells
transfected with pDZ-HA (Cal/09). Positive hybridomas were
subcloned and re-tested. To generate 1918 virus HA-specific
antibodies, mice were immunized by DNA vaccination with
pCAGGS-HA of the influenza A/South Carolina/1/18 H1N1
virus and then boosted with whole inactivated virus as above.
Hemagglutination inhibition (HI) assays were used to select cross-
reactive antibodies against homologous HA using 1918 VLPs. The
1918 HA-specific mAbs 6B9 and 39E4 correspond to isotype
IgG2a and the Cal04/09 mAb 29E3 correspond to an IgG2b
isotype. The mAbs were isotyped using the IsoStrip kit (Roche,
Indianapolis, IN) and purified using a Protein A sepharose
column.
Hemagglutination inhibition assay
Mouse sera were inactivated using a trypsin-heat-periodate
treatment as previously described [31]. Briefly, one volume of sera
was mixed with half a volume of trypsin 8 mg/ml (Sigma-Aldrich,
St. Louis, MO) in 0.1 M phosphate buffer, pH 8.2 and then
incubated for 30 min at 56uC. The samples were allowed to cool
to room temperature (RT) and were mixed with 3 volumes of
0.11 M metapotassium periodate and incubated at RT for 15 min.
Three volumes of 1% glycerol saline were then added and mixed
with the samples and further incubated for 15 min at RT. The
samples were diluted to a final 1:10 dilution by adding and mixing
2.5 volumes of 85% saline. HI assays of mAbs and sera were
conducted following standard protocols [30]. Two-fold serial
dilutions of sera or mAbs were mixed and pre-incubated in 96-well
plates for 30 min at 4uC with 8 HA units of virus per well. Turkey
red blood cells were added to a final concentration of 0.25%, and
the plate was incubated on ice for 30 min. Hemagglutination
inhibition (HI) titers of sera were determined as the highest
dilution that displayed hemagglutinating activity. Specific HI
activity of mAbs was calculated as the lowest concentration of
mAb that displayed hemagglutinating activity.
Generation of mAb escape mutants
mAb escape mutants were generated as previously described
[32]. Briefly, Cal/09 (6:2) virus was incubated with excess
monoclonal antibody for 1hr at room temperature. The virus-
mAb mix was inoculated into 10 day old embryonated eggs and
incubated at 37uC for 48 hrs. The virus (allantoic fluid) grown
under this conditions was harvested and re-tested for loss of HI
activity against the same mAb used for selection. Mutations in the
HA responsible for the Ab escape were identified by direct
sequencing of vRNA obtained by RT-PCR.
Mice experiments
Infections, body weight loss and survival. BALB/C or
C57B/6 mice (Jackson Laboratories, Bar Harbor, ME) were
anesthetized with ketamine-xylaxine and intranasally infected with
the indicated dose of virus diluted in 50 ml of PBS. Body weight
and survival were measured every day for 14 days. All mouse
experiments were carried in strict accordance with institutional
protocols. Mice showing more than 25% of body weight loss were
considered to have reached the experimental end point and were
humanely euthanized.
Lung titers. Lungs of infected mice were excised on indic-
ated days post-infection and homogenized using a mechanical
1918-Like Viruses Protect against 2009 SOIV H1N1
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the homogenates were quantified by plaque assay on MDCK cells.
Each data point presents the average titer from 2–3 mice.
Determination of LD50 for Neth/09. Female C57B/6 mice
(9 weeks old) were anesthetized with ketamine-xylaxine and
intranasally infected with doses 5610
2,5 610
3,5 610
4,5 610
5 or
5610
6 pfu virus in 50 ml (n=5/group). The mice were monitored
daily for survival and body weight loss over a period of 14 day post
infection (p.i.) Mice showing more than 25% of body weight loss
were considered to have reached the experimental end point and
were euthanized. LD50 were calculated by the Reed & Muench
method [33].
Vaccination and challenge. Five-week-old female C57B/6
were immunized with 15 mg of inactivated virus or 1918 VLP by
intramuscular injection in the hind leg. Two-weeks later the mice
were boosted with the same amount of inactivated virus. Four
weeks after the initial immunization mice were challenged with
Neth/09 at a dose equivalent to 50 LD50 (7.9610
5 pfu). Survival
and body weight loss were monitored for 14 days. Mice were 9–10
week old at the time of lethal challenge.
Passive immunization and challenge. Monoclonal
antibodies 6B9 and 39E4 were generated against influenza A/
South Carolina/1/18 (H1N1) virus (1918) HA, and monoclonal
antibody 29E3 was raised against Cal/09 HA. Nine-week-old
C57B/6 mice were passively immunized with a total 150 mgo f
indicated monoclonal antibody (intraperitoneally) or 200 mlo f
polyclonal sera from mice previously infected with Cal/09, 24h
prior to lethal challenge. A mAb (isotype IgG2a) raised against an
unrelated viral protein, Nipah W, was administered as control.
The mice were challenged with Neth/09 at a dose equivalent to 50
LD50. Survival and body weight loss were monitored for 14 days
post challenge (p.c.), and lung viral titers were obtained at days 3
to 6 p.c.
Control group. All of the vaccinated and passively
immunized mice were challenged at the same time. A single
group of control mice were used for comparison in both
experiments and refer to either ‘‘No vaccination’’ or ‘‘No Ab’’
controls shown below.
Homology modeling
The structural models for HA of Cal//09 and Bris/59/07 were
generated using structural automated protein structure homology-
modeling prediction server (Swiss-Model) with best fitting
templates (PDB: 1ruy for Cal/09 and 1rvx for Bris/59/07) [34].
The structure of 1918 HA was obtained from PDB (PDB ID:
2wrg). The final images of the HA structures were generated using
Pymol (Delano Scientific) [35].
Results
Characterization of 2009 pandemic H1N1 isolates in mice
To evaluate the virulence and infection kinetics of novel
pandemic H1N1 viruses in mice, six-week old BALB/c and
C57B/6 mice were infected with two virus isolates of 2009 H1N1
and monitored for signs of body weight loss and survival.
Inoculation of BALB/c mice with Cal/09 isolate produced a
marked decrease in body weight even at 10
3 pfu (,13%, Fig. 1A),
a phenomenon not commonly observed with non-mouse adapted
human H1N1 viruses [36]. When infected with 5610
4 pfu 50% of
the mice reached the experimental end point of .25% weight loss
by day 9 (Fig. 1C). The remaining mice showed substantial weight
loss by day 8 p.i., with an average weight of 77.5% (Fig. 1A). Viral
lung titers in these mice at both day 2 and 5 were notably high
with no significant difference at both time points (Fig. 1D). Similar
results were observed in C57B/6 mice after inoculation with Cal/
09 virus. At doses of 10
3 and 5610
4 pfu mice showed body weight
losses comparable to those of BALB/c mice (Fig. 1B). The viral
titers in the lungs of C57B/6 mice were almost ten-fold higher on
day 6 p.i. than on day 3 p.i. (Fig. 1D), indicating active replication
of virus. As with BALB/c mice, infection with 5610
4 pfu resulted
in 50% of mice reaching the experimental end point by day 8 p.i.
(Fig. 1C), and an average weight loss of 21.8% on day 7 p.i.
(Fig. 1B).
To evaluate whether similar virulence is observed with other
isolates of 2009 pandemic H1N1, we infected mice with the Neth/
09 isolate. Interestingly, Neth/09 showed a considerably higher
virulence in C57B/6 mice. At a dose of 5610
4 pfu/ml, the mice
exhibited rapid and substantial weight loss by day 4 (Fig. 1B). All
mice succumbed to infection or reached experimental end point
by day 6 p.i. (Fig. 1C), and had higher lung viral titers than those
observed with the Cal/09 isolate at this time point (Fig. 1E).
To further evaluate the pathogenesis of Neth/09, we next
determined the LD50 of Neth/09 isolate in mice. Nine-week old
female C57B/6 mice were infected with different doses of virus
(5610
2,5 610
3,5 610
4,5 610
5 or 5610
6 pfu) and monitored for
weight loss and survival over a period of 14 days p.i. (Fig. 2A and
B). All mice inoculated with 5610
4 pfu or higher succumbed to
infection or reached the experimental end point between days 4–8
p.i. (Fig. 2A). Mice inoculated with 5610
3 pfu showed a 12.2%
decrease in body weight, and mice infected with 5610
2 pfu
showed no significant drop in weight (Fig. 2B). The LD50 for
Neth/09 was determined to be 1.58610
4 pfu for 9-week-old
C57B/6 mice (Reed and Muench method, [33]). Overall, these
data indicates that the Neth/09 isolate is more pathogenic in mice
than Cal/09 and thus, in the challenge experiments described
herein, the Neth/09 isolate and C57B/6 mice were used as a
lethal model for 2009 pandemic H1N1.
Antigenic cross-reactivity of 2009 pandemic H1N1 viruses
Next, to evaluate the level of antigenic resemblance between
2009 H1N1 viruses and other H1N1 viruses, we performed
hemaglutination inhibiton (HI) assays and challenge experiments.
Analysis of sera from mice infected with Cal/09 revealed similar
levels of HI activity against the Cal/09 and Neth/09 isolates,
suggesting that they are antigenically very similar, despite
significant differences in pathogenicity in mice (data not shown).
As a proof of principle and to establish if prior infection with
Cal/09 is sufficient to confer protection against a lethal challenge
with an antigenically similar Neth/09 isolate, C57B/6 mice were
first infected with Cal/09 and allowed to seroconvert for 21 days,
followed by lethal challenge with 10
6 pfu of Neth/09 (.50 LD50).
As expected, all mice previously infected with Cal/09 survived
(Fig. 2D). Mice previously inoculated with 10
3 pfu of Cal/09
showed a decrease of 10% body weight. However, all the mice
regained the weight by day 6 (Fig. 2C). No significant weight
change was observed in the 5610
4 pfu group. In contrast, mice
previously mock infected succumbed to Neth/09 challenge by day
8 (Fig. 2D). Together, this demonstrates that Cal/09 and Neth/09
are antigenically very similar and there is cross-protection between
different 2009 pandemic H1N1 isolates.
Vaccination with 1918-like or classical swine H1N1 viruses
confers protection against Neth/09 lethal challenge
Recent serological studies have shown that the human
population under the age of 30 has little or no level of neutralizing
antibodies against the 2009 pandemic H1N1 virus [22,27,28,37].
However, sera from adults older than 35 years of age showed
varied levels of neutralizing activity to 2009 pandemic H1N1, with
1918-Like Viruses Protect against 2009 SOIV H1N1
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activity [27]. To investigate if antibodies against older H1N1
viruses can cross-react with and therefore offer protection against
the 2009 pandemic H1N1 virus, C57B/6 mice were immunized
with 1918 VLP or different inactivated H1N1 virus vaccines,
spanning from 1918–2009. Prior to lethal challenge, all mice were
tested for seroconversion against the homologous virus and were
found to have HI antibody titers equivalent to $40 (Table 1). To
test if vaccination with any of the other H1N1 viruses offered
protection against novel 2009 pandemic H1N1, immunized mice
were challenged with a lethal dose of Neth/09 (50 LD50), and the
vaccine efficacy was evaluated by assessment of weight loss and
survival over a 14 day period p.c., and also by measuring the virus
titer in the lower respiratory track (Fig. 3). In the no vaccination
group (control), mice succumbed to infection and reached the
experimental endpoint by day 5 (Fig. 3B). This group of mice
showed the highest viral titers in the lungs at days 3 and 6 p.c.
(Fig. 3C). As anticipated immunization with Cal/09 6:2 offered
full protection from death to mice (Fig. 3B). Modest levels of
disease were observed in this group as evidenced by a decrease in
body weight (Fig. 3A). However, we did not detect infectious virus
in the lungs of these mice on days 3 or 6 p.c. (Fig. 3C; limit $10
pfu). Interestingly, inactivated classical swine H1N1 viruses (Sw/
30 or NJ/76), 1918 VLPs and an inactivated human H1N1 virus
isolated in 1943 (Wei/43) offered 100% protection against death
from 2009 pandemic H1N1 challenge. The 1918 VLP-vaccinated
mice all survived and showed weight loss comparable to that of the
Cal/09 6:2 vaccinated animals (Fig. 3B and 3A). We detected 100-
fold lower levels of virus in the lungs of challenged mice on day 3
p.c. and no virus on day 6 p.c. Similarly, in mice immunized with
Sw/30 or NJ/76, Neth/09 virus was only detected in the lungs on
day 3 p.c., indicating that these two vaccines had an efficacy in
reducing viral replication in lungs comparable to that of 1918
VLPs (Fig. 3C). However, a slightly higher weight loss (,18.2%)
was observed in these groups (Fig. 3A). Although vaccination with
Wei/43 resulted in 100% survival, these mice showed a much
greater and sustained weight loss than the 1918 VLP, SW/30 and
NJ/76 vaccinated mice, and the viral titers in the lungs were high
on both day 3 and day 6 p.c., suggesting only modest levels of
inhibition of Neth/09 virus replication (Fig. 3A, B and C). In
contrast, immunization with human H1N1 viruses that circulated
from 1977–2007 showed only partial protection against lethal
Neth/09 challenge (Fig. 3E). This was evidenced by extensive
weight loss observed in these mice (Fig. 3D). In mice vaccinated
with USSR/77, Hou/84, Tx/91 or Bris/59/07 only 20–60%
survival was observed (Fig. 3D and E). The viral titers on day 3
p.c. were similar to controls. Nevertheless, on day 6, viral titers
were lower, particularly in the Tx/91 vaccinated mice that had
around 1000-fold lower viral titers as compared to day 3 p.c.
(Fig. 3F). In the groups vaccinated with the NT/68 and Bris/10/
07 strains, viruses belonging to the H3N2 subtype, lethal challenge
resulted in either a 25% survival or all mice succumbing to
infection, respectively. In agreement with the increased morbidity
seen in Bris/10/07 vaccinated mice, weight loss and viral titers
Figure 1. Differences in pathogenicity of 2009 pandemic H1N1 virus isolates in mice. (A) Body weight of BALB/c mice infected with the
Cal/09 isolate. Six-week old BALB/c mice were infected with indicated dose of virus and body weights were monitored everyday as measure of virus
induced disease. (B) Neth/09 isolate is more pathogenic than Cal/09 isolate in mice. C57B/6 mice were infected with either Cal/09 or Neth/602 isolate
of 2009 pandemic H1N1 virus at indicated doses. (C) Comparison of survival rates of BALB/c and C57B/6 mice infected with Cal/04 and Neth/602
viruses. (D) Viral titers in the lungs of BALB/c mice infected with either 1610
3 or 5610
4 pfu of the Cal/09 isolate. (E) Viral titers in the lungs of C57B/6
mice infected with either 1610
3 or 5610
4 pfu of Cal/09 or 5610
4 pfu of Neth/09. ND indicates that data was not determined. The body weights were
measured everyday and are represented as a percentage of body weight prior to infection (n=4 or 5 mice/group). Mice showing more than 25% of
body weight loss were considered to have reached the experimental end point and were humanely euthanized. The lungs of 2–3 infected mice were
excised and viral loads in the homogenates were measured by performing plaque assay in MDCK cells.
doi:10.1371/journal.ppat.1000745.g001
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vaccination group on day 6 p.c. are unclear (Fig. 3F). Nevertheless,
these results indicate that inactivated vaccines based on classical
swine H1N1 viruses and on human 1918 and 1943 H1N1 viruses
protect against death in mice infected with the 2009 pandemic
H1N1 virus and suggest that they likely share significant antigenic
similarity.
Next, to test whether the protection observed in 1918–1943 and
NJ/76 vaccinated correlates with cross-reactive neutralizing
antibodies in the sera, we tested the pre-challenge sera from
vaccinated mice for HI activity against different H1N1 viruses
(Table 2). All the pre-challenge sera showed HI titer between 160–
2560 against the homologous virus. As expected, sera from 1918
VLP, SW/30 and NJ/76 vaccinated animals showed HI activity
against both 2009 H1N1 pandemic viruses (HI titer $40),
suggesting that protection is due to cross-reactive antibodies.
However, despite complete protection against death from Neth/09
lethal challenge, the sera from Wei/43 showed no HI activity
against 2009 H1N1 viruses. This might indicate that the HI assay
is less sensitive than the challenge assay in vivo to evaluate the
presence of protective Abs. Taken together, our results demon-
strate that 1918, SW/30 and NJ/76 share antigenically similar
epitope(s) that might be responsible for the cross-protection.
Passive immunity with 1918 mAb protects against Neth/
09 lethal challenge
To further examine the common possible epitopes shared
between 1918 and 2009 H1N1 viruses, we examined cross-
reactivity of 1918 HA-specific monoclonal antibodies with Cal/09
by HI assay. Two 1918 HA mAb’s, 6B9 and 39E4, showed HI
activity against Cal/09. Also, one of the Cal/09 HA specific
antibodies (29E3) showed HI activity against Cal/09 and against
1918 VLPs (Table 3). To evaluate if these mAbs could confer
protection (in vivo) against lethal Neth/09 challenge, mice were
given 150 mg of mAb as a prophylactic treatment 24h prior to
challenge (50 LD50). To assess the level of HI titers in the blood
prior to challenge, the HI activity in passively immunized mice
sera was measured (Table 4). Sera from mice immunized with an
Figure 2. Prior infection with Cal/09 virus cross-protects mice against the lethal challenge with Neth/09 isolate. (A, B) Determination of
LD50 for the Neth/09 isolate in C57B/6 mice (n=5/group). Mice were infected with the indicated doses of virus and their body weight (A) and survival
(B) were monitored for 14 days. (C, D) Re-challenge of Cal/09 infected mice with Neth/09 (n=4/group). Six weeks old C57B/6 mice were inoculated
with PBS (Mock) or Cal/09 isolate (10
3 or 5610
4 pfu). After 21 days the mice were challenged with 1610
6 pfu of Neth/09 isolate. The body weight (C)
and survival (D) were monitored for 14 days as in Fig. 1.
doi:10.1371/journal.ppat.1000745.g002
Table 1. HI activity of mice sera against homologous virus
post-vaccination.
Virus HI titer
a,b (Pre-challenge)
1918 VLP 40–320
Sw/30 40–160
Wei/33 640–1280
NT/68 40–640
NJ/76 80–320
USSR/77 640
Hou/84 80–640
Tx/91 160–640
Bris/59/07 80–640
Bris/10/07 320–640
Cal/09 40–2560
aRange of HI antibody titer of 10 vaccinated mice per group.
bHI titers represent the highest dilution that displayed hemagglutination
inhibitory activity.
doi:10.1371/journal.ppat.1000745.t001
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did not show HI activity. Mice immunized with HA-specific
monoclonal antibodies showed considerable levels of HI titers
(HI=40–320). Mice immunized with polyclonal sera showed a
lower HI titer (HI=20–80; Table 4). As expected, administration
of the control antibody resulted in no protection from lethal
challenge and all mice had high virus titers in the lungs equivalent
to those seen in untreated mice (Fig. 4). Polyclonal sera from mice
previously infected with Cal/09 virus were used as a positive
control prophylactic treatment to establish the baseline of
protective antibodies in vivo (Poly sera). Mice in this group were
completely protected from lethal challenge and showed a decrease
in lung virus titers on day 3 and 6 compared to untreated controls.
Nonetheless, these mice showed a significant weight loss during the
first 4 days (Fig. 4A, B and C). Treatment with 150 mg of 1918
specific anti HA monoclonal antibodies (6B9 and 39E4) also
conferred full protection from challenge and showed reduced
weight loss as compared to the polyclonal sera treatment group.
The Cal/09 specific monoclonal antibody (29E3) treatment
resulted in 100% survival and no weight loss, indicative of little
or no morbidity in these mice. Assessment of infectious virus in the
lower respiratory track of mice treated with all monoclonal
Figure 3. Vaccination of mice with 1918, 1943 and classical swine H1N1 virus-based inactive vaccines protects against Neth/09
lethal infection. Five weeks old C57B/6 were immunized with 15 mg of the indicated inactivated viruses or with 1918 VLP vaccine followed by a
boost (15 mg) after two weeks. Four weeks after the first immunization, vaccinated mice were challenged with Neth/09 isolate at a dose of 50 LD50
(7.9610
5 pfu). Mice were monitored for body weight loss and survival for 14 days as in Fig. 1. (A) Body weight of classical swine H1N1 (Sw/30, NJ/76),
1918 VLP and human H1N1 Wei/43 vaccinated mice after challenge with Neth/09 (n=4 or 5 mice/group) (D) Body weight of mice vaccinated with
contemporary (from 1977–2007) H1N1 or H3N2 inactivated virus after challenge with Neth/09 (n=4 or 5 mice/group). (B, E) Survival of mice
vaccinated with H1N1 and H3N2 viruses post-challenge. (C, F) Viral titers in H1N1 and H3N2 vaccinated mice on days 3 and 6 p.c. Each data point
represents the average viral titers from 2 or 3 mice. A single group of control (no vaccine) mice were used and are included in all the panels for direct
comparison. The Cal/09 vaccinated group is also included on (A) and (B) for comparison.
doi:10.1371/journal.ppat.1000745.g003
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especially on day 3 p.c. (Fig. 4C). Taken together, these data
suggest that cross-reactive monoclonal antibodies protect against
lethal Neth/09 challenge by blocking a conserved antigenic site
between 1918 and 2009 pandemic H1N1 viruses.
Mapping of cross-protective epitopes
To identify the shared cross-protective epitope(s) in HA, we
generated mAb escape mutants of Cal/09 6:2 virus. Escape
mutants generated by pre-incubation of Cal/09 virus (6:2) with
excess of each of the cross-reactive mAbs (6B9, 39E4 and 29E3)
resulted in a loss of HI activity against the same mAb. Of interest,
all the escape mutant viruses generated with either 1918- or 2009
HA-specific mAbs carried mutations in the antigenic site Sa
(Table 5; Fig. 5). The escape mutants that arose in the presence of
the 1918 specific mAb 6B9 and 39E4 contained mutations G172E
(G158E by H3 numbering) and K171E (K157E by H3
numbering), respectively. The escape mutants generated by
selection with the 2009 H1N1 specific mAb (29E3) carried either
a K171E or K171Q or K180N mutation (residues K171 and
K180 correspond to K157 and K166 in H3 numbering). These
results indicate that all the mAbs bind to the conserved antigenic
site Sa (Fig. 5 and 6).
Discussion
Seasonal influenza viruses predominantly cause severe disease in
very young children and in the older population. However,
infections with the 2009 pandemic H1N1 are considerably lower
in people 65 years or older, likely due to immunity from prior
exposure and/or vaccination to an antigenically similar influenza
virus [24,25,26]. Using a panel of 11 different influenza viruses from
1918–2009, we tested the ability of inactivated vaccines based on
these viruses to protect against a mouse-lethal 2009 pandemic
H1N1. Here, we show that vaccination of mice with human 1918
influenza virus VLPs, and inactivated human Wei/43 and classical
swine H1N1 viruses completely protects from death by lethal
challenge with the 2009 pandemic H1N1. Also, analysis of pre-
challenge sera from mice vaccinated with these viruses, except Wei/
43,show cross-reactivityagainstthe2009H1N1virus(HItiter$40).
In contrast, vaccination with more contemporary H1N1 viruses
Table 2. HI activity of polyclonal sera from mice vaccinated against different H1N1 isolates.
HI titer of mouse sera
a,b
Virus 1918 VLP Sw/30 Wei/43 NT/68 NJ/76 USSR/77 Hou/84 Tx/91 Bris/59/07 Cal/09 Neth/09
c Control
d
1918 VLP 160 40 ,10 ,10 20 ,10 ,10 ,10 ,10 320 80 ,10
Sw/30 20 160 ,10 ,10 80 80 ,10 ,10 ,10 10 ,10 ,10
Wei/33 ,10 ,10 1280 ,10 ,10 ,10 20 ,10 ,10 ,10 ,10 ,10
NT/68
e ,10 ,10 ,10 640 ,10 ,10 ,10 ,10 ,10 ,10 ,10 ,10
NJ/76 10 80 ,10 ,10 320 ,10 ,10 ,10 ,10 80 ,10 ,10
USSR/77 ,10 ,10 ,10 ,10 ,10 640 ,10 ,10 ,10 ,10 ,10 ,10
Hou/84 ,10 ,10 ,10 ,10 ,10 40 320 ,10 ,10 ,10 ,10 ,10
Tx/91 ,10 ,10 ,10 ,10 ,10 ,10 ,10 640 ,10 ,10 ,10 ,10
Bris/59/07 ,10 ,10 ,10 ,10 ,10 ,10 ,10 ,10 640 ,10 ,10 ,10
Cal/09 160 80 ,10 ,10 40 ,10 ,10 ,10 ,10 2560 640 ,10
Neth/09 160 80 ,10 ,10 40 ,10 ,10 ,10 ,10 640 1280 ,10
aHI titers represent the highest dilution that displayed hemagglutination inhibitory activity.
bPositive titers are bolded for clarity.
cHI activity of sera from mice infected with Neth/09 is included for comparison.
dControl- negative sera.
eH3N2 strain representative used in the vaccination studies.
doi:10.1371/journal.ppat.1000745.t002
Table 3. HI activity of anti-HA monoclonal antibodies used
for passive immunity treatment.
Antigen specificity Antibody Cal/09 6:2 Bris/59/07 1918 VLPs
1918 HA
a 6B9 0.15 .5 0.15
39E4 0.15 .5 0.15
Cal/09 HA
a 29E3 0.04 .5 0.08
Nipah W
a Control .5 .5n / d
b
aSpecific HI activity of mAbs was calculated as the lowest concentration (mg/ml)
of mAb that displayed hemagglutination inhibitory activity.
bn/d: not determined.
doi:10.1371/journal.ppat.1000745.t003
Table 4. In vivo HI titers in passively immunized mice pre-
challenge.
Antigen Specificity Antibody HI Titers
a
1918 HA 6B9 n/d
b
39E4 40–320
Cal/09 HA 29E3 160–320
Nipah W Control ,10
Cal/09 virus Sera 20–80
N/A
b Sera (Negative) ,10
aHI titers represent the highest dilution that displayed hemagglutination
inhibitory activity.
bN/A: Not applicable, n/d: not determined.
doi:10.1371/journal.ppat.1000745.t004
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with 1918 HA-specific monoclonal antibodies protects against the
2009 H1N1 virus, suggesting antigenic similarity between these
viruses. Cross-protective epitope mapping shows that 1918 HA-
specificmAbsprotectbybinding to theconservedantigenicsiteSain
2009 H1N1 virus. Based on our HI data (Table 2) and since
inactivated vaccines are known to induce protective humoral and
minimal cellular immunity, this protection was likely mediated by
antibodies, as also evidenced by the lack of complete protection by
H3N2-based vaccines. Our results indicate that prior exposure to
human influenza A viruses from 1918–1943 or vaccination with
classical swine H1N1 virus (NJ/76) offers significant levels of cross-
protection against the novel 2009 H1N1 pandemic virus and thus
provides a mechanisticexplanation for the lowerincidenceofdisease
and/or infection seen in people aged 65 or older.
Usually human influenza viruses do not show substantial
replication in mice without prior adaptation to this host [36].
Only a few viruses including 1918 and highly pathogenic H5N1
viruses have been shown to replicate efficiently and cause severe
pathogenicity [38]. The current 2009 pandemic H1N1 shows
active replication and pathogenesis in mice. However, there
appear to be differences in the pathogenicity and transmission of
2009 H1N1 isolates in different animal models [39,40,41]. In this
study we have established a lethal mouse model for the 2009
pandemic H1N1 virus and demonstrate differences between the
Cal/09 and Neth/09 viruses in terms of mouse virulence. Mice
infected with Neth/09 showed an early and dramatic loss in body
weight and succumbed to infection or reached the experimental
end point by day 6 (Fig. 1B and C; Fig. 2A and B). Cal/09 and
Neth/09 viruses were both isolated from humans showing mild
upper respiratory symptoms and their genomes only differ at eight
amino acid positions [39,40]. The reasons for the differences in
mouse virulence between these two isolates remains unclear.
Despite these differences, antigenicity based on HI cross-reactivity
between the two virus isolates is similar. This is in agreement with
recent reports from the World Health Organization stating that all
Figure 4. Passive immunization of mice with 1918 and 2009 H1N1 HA specific cross-reactive antibodies protects against Neth/09.
Nine week old, C57B/6 mice were passively immunized with a total 150 mg of indicated monoclonal antibody (intraperitoneal route) 24 hr prior to
viral challenge. After antibody administration, the mice were challenged with Neth/09 isolate at a dose 50 LD50. (A) Body weight of passively
immunized mice challenged with Neth/09 (n=5/group). (B) Survival of passively immunized mice post-challenge with Neth/09. (C) Viral Titers in the
lungs at days 3 and 6 p.c. Viral load in the lungs homogenates were quantified as in Fig. 1. Control (No Ab) mice are the same as controls in Fig. 3 and
are included for direct comparison.
doi:10.1371/journal.ppat.1000745.g004
Table 5. Cross-reactive mAb escape mutants of Cal/09.
Antigen Specificity Antibody Mutation
a
1918 HA 6B9 G172E (G158E)
39E4 K171E (K157E)
Cal/09 HA 29E3 K171E (K157E)
K171Q (K157Q)
K180N (K166N)
aH3 numbering are shown in parenthesis.
doi:10.1371/journal.ppat.1000745.t005
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PLoS Pathogens | www.plospathogens.org 9 January 2010 | Volume 6 | Issue 1 | e1000745Figure 5. Comparison of the conservation of antigenic sites in HA of H1N1 viruses. Alignment of HA sequences from USSR/77, Tx/91, Bris/
59/07 and 2009 human H1N1 viruses (top panel). Alignment of HA sequences from 1918, Sw/30, Wei/43, NJ/76 and 2009 H1N1 viruses (bottom
panel). The antigenic sites are indicated in colored shaded boxes and were previously described by Brownlee and Fodor [42], using H3 numbering, as
Cb (78–83), Sa (128–129, 156–160, 162–167), Sb (187–198), Ca1 (169–173, 206–208, 238–240) and Ca2 (140–145, 224–226).
doi:10.1371/journal.ppat.1000745.g005
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PLoS Pathogens | www.plospathogens.org 10 January 2010 | Volume 6 | Issue 1 | e1000745Figure 6. Comparison of antigenic differences in the HA structures of 1918, Cal/09 and Bris/59/07 viruses. (A) Ribbon representation of
an HA monomer (H1 and H2) of the three viruses. Individual antigenic sites are highlighted by green ellipses in the HA monomers. (B) Top panel:
Zenithal surface top view of HA trimeric complexes depicting antigenic sites and their differences among 1918, Cal/09 and Bris/59/07 viruses. Blue
color corresponds to conserved amino acids and red color represents amino acids that differ from 1918 HA. The antigenic sites are colored in light
blue. Bottom panel: Close-up view of antigenic site Sa in monomeric 1918 and Cal/04 HAs. Amino acids K171, G172 and K180 (K157, G158 and K166
by H3 numbering) corresponding to mAb escape mutations are shown in yellow.
doi:10.1371/journal.ppat.1000745.g006
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ically similar (www.who.int).
Although at this moment we can not exclude the possibility that
the NA protein contributed at least in part to the protection seen
with the inactivated vaccines, our results from the passive
immunization and vaccination studies suggest that human H1N1
viruses from or prior to 1943, including the 1918 virus, share
common protective epitope(s) in the HA protein. The antigenic
sites of influenza virus HA’s has been extensively characterized by
monoclonal antibody epitope mapping studies [32,42]. Interest-
ingly, sequence alignment of the HAs from 1918, Sw/30, NJ/76
and 2009 H1N1 viruses showed a high degree of similarity in the
known antigenic sites (Fig. 5, bottom). To further understand the
antigenic relatedness between 1918 and 2009 H1N1 viruses, we
compared the structure of the 1918 HA with the predicted HA
structures of Cal/09 and Bris/59/07 (Swiss-Model; Fig. 6A). It is
apparent that the globular head regions of HA’s, that harbor the
known antigenic sites, share close similarities between the Cal/09
and 1918 viruses (Fig. 6A and B). However, the antigenic sites in
Bris/59/07 HA contain several amino acid changes as compared
to the 1918 HA (evidenced from the higher number of red colored
residues, Fig. 6B, top panel). This is supported by analysis of the
pre-challenge sera from mice vaccinated with 1918 VLP that show
high cross-reactivity against 2009 H1N1 virus (Table 2). Although
the Wei/43 vaccine conferred complete protection from death,
Wei/43 HA shows less sequence similarity to the 2009 H1N1 HA
in the antigenic sites as compared to 1918 and the sera from Wei/
43 vaccinated animals showed no cross-reactivity with 2009 H1N1
viruses by HI assay (Fig. 5; Table 2). In agreement with our
findings, Wei/43 vaccinated animals showed more morbidity and
higher viral titers after Neth/09 challenge than Cal/09 and 1918
vaccinated mice. Thus, Wei/43 appears to have a slightly
decreased protective effect, suggesting that circulation of H1N1
viruses in humans for approximately 2 decades (after the 1918
pandemic) resulted in sufficient drift leading to considerable loss
of antigenic cross-reactivity. One would therefore predict that
H1N1 viruses that have circulated in the human population
beyond the 1950’s would offer little or no protection against the
2009 pandemic H1N1. Although, there is a correlation between
sequence identity in the antigenic sites and protection, it is possible
that some of the changes in the antigenic sites may not contribute
to the overall alterations in antigenicity. In contrast to 1918 and
classical swine H1N1 viruses, alignment of 2009 H1N1 with H1N1
HAs from viruses isolated in humans after 1977 showed significant
variations in the antigenic sites especially in sites Sa and Sb
(Fig. 6A, top). This is in agreement with our results showing that
contemporary H1N1 virus vaccines only offered partial protection
in mice against Neth/09 challenge and that surviving mice showed
greater morbidity as evidenced by a more dramatic and sustained
weight loss (Fig. 3D). Of interest, two of the more recent viruses,
Tx91 and Hou/84, showed nearly 60% protection from death in
mice to Neth/09 challenge. However, the reasons for this better
partial protection offered by these two virus vaccines are unclear.
Nevertheless, similar partial protection from lethal challenge has
been previously described for antigenically different H1N1 viruses
[43]. The mechanism for this partial protection is unclear and has
been speculated to be largely due to anti-HA immunity [43]. Also,
we cannot rule out completely the possible roles of T-cell mediated
immunity or anti-NA-specific antibodies [44,45,46,47,48]. This
warrants further investigation.
To characterize the antigenic similarity, we generated mAbs
against the HA of 1918 and 2009 H1N1 viruses. Interestingly,
two 1918 HA-specific mAbs, 6B9 and 39E4, and one Cal/09 HA
specific mAb, 29E3, showed HI activity against both 1918 VLP
and Cal/09 virus (Table 4). Passive immunization of mice with
both 1918 HA-monoclonal antibodies afforded complete pro-
tection against lethal Neth/09 challenge and a 100–1000 fold
reduction in viral titers in the lower respiratory track of mice.
However, we did notice a loss in body weight starting on day 4–6
and an increase in lung titers on day 6, likely due to waning of
neutralizing antibody levels in the sera. In the case of polyclonal
sera treatment, the HI titers in the blood prior to challenge were
4-fold lower than monoclonal antibody treatment. In agreement
with the lower HI titer, we observed an initial decrease in body
weight up to 4 days following Neth/09 challenge. All these mice
started recovering weight by day 5. Despite lower HI titers in the
sera prior to challenge, the polyclonal sera treated mice had lung
titers 1000 fold lower than control mice. This could be due to the
action of NA specific antibodies which have been demonstrated
to play a protective role [46], and to other HA specific antibodies
without HI activity. The ability of 1918 HA specific antibodies to
neutralize the 2009 pandemic H1N1 further confirms the close
antigenic relationship of these viruses. Indeed, by generating
antibody escape mutant viruses of Cal/09, we mapped antigenic
s i t eS aa st h ec r o s s - r e a c t i v ee p i t o p e( T a b l e5a n dF i g .6 B ) .
Overall, this highlights theapparent slower pace ofantigenic drift
of the classical swine H1N1 viruses since their introduction into
the pig population over 90 years ago, most likely due to the
absence of pre-existing immunity in the majority of this
population.
In 1976, an H1N1 virus closely related to classical swine H1N1
isolates from the 1930’s caused an influenza outbreak at an
American military facility, Fort Dix, in the state of New Jersey.
After the 1976 swine H1N1 outbreak, nearly 40 million people in
the United States were immunized with an NJ/76 vaccine. Our
study in mice, in agreement with previous serology done with
ferret sera [49], shows that immunization with NJ/76 vaccine
protected from 2009 pandemic H1N1 lethal challenge, and
therefore it is likely that people carrying antibodies against the
NJ/76 will be protected against the 2009 H1N1. Additionally, sera
from adults immunized with NJ/76 vaccine cross-neutralized the
2009 H1N1 [27].
Two recent human serology studies showed a high prevalence of
neutralizing antibodies against 2009 pandemic H1N1 in people
born before 1930 [28,39]. Our data reveals that immunization
with human H1N1 viruses that circulated before 1945 (e.g. specific
antibodies against 1918 and Wei/43) is sufficient for immune
protection from the 2009 pandemic H1N1. These findings provide
a rationale for the epidemiological data arising from different parts
of the world that have indicated a consistently higher rate of
infection with this novel virus in the younger population (,35 of
age), due to the lack of previous exposure to any of the
antigenically-related viruses described above. As such, these results
greatly emphasize that vaccination efforts and resources should
also be directed at this susceptible population.
Our data are consistent with a picture in which domestic pigs
have served as a reservoir for an ‘‘antigenically frozen’’ H1
hemagglutinin derived from the 1918 influenza virus. A significant
drift in humans of that same 1918 H1N1 virus has resulted in a
lack of significant pre-existing immunity against the 2009
pandemic H1N1 virus in humans born after the 1940–50s. Of
concern, swine influenza viruses containing HA genes derived
from more modern human H3 and H1 viruses have also
established lineages in North American pigs during 1997–1998
and 2003–2005, respectively [13]. Also, human H3 viruses have
established stable lineages in European swine populations after the
1968 ‘‘Hong Kong’’ pandemic, and are still circulating in the form
of human-avian H3N2 reassortant viruses [50]. It is possible that
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leading to potential human pandemic H3 and H1 viruses in the
future [51,52]. As such, surveillance and containment of swine
influenza viruses is desirable for the prevention of future pandemic
episodes.
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